Specify a stock or a cryptocurrency in the search bar to get a summary
Perseus Proteomics Inc.
4882Perseus Proteomics Inc., a drug discovery biotech venture company, develops antibody drugs against cancer and other diseases in Japan. The company is involved in the antibody discovery activities; and antibody research support activities comprising hybridoma antibody sequencing, antibody protein production, and contract antibody research activities, as well as supply of antibody products. Its product pipeline includes PPMX-T001, an anti-hepatocarcinoma antibody; PPMX-T002, an anticancer drug; PPMX-T003, a drug for the treatment of adult T-cell; and PPMX-T004, an antibody drug conjugate. The company was incorporated in 2001 and is headquartered in Tokyo, Japan. Address: 30-1 Nihonbashi Hakozakicho, Tokyo, Japan, 103-0015
Analytics
WallStreet Target Price
124 798 JPYP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures 4882
Dividend Analytics 4882
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History 4882
Stock Valuation 4882
Financials 4882
Results | 2019 | Dynamics |